Secarna Pharmaceuticals Presents Data at SITC Demonstrating the Potential of Antisense Oligonucleotides in Targeting NRP1

Neuropilin-1 (NRP1), implicated in various pro-tumorigenic processes, is a promising therapeutic target for cancer treatmentSecarna designed LNA-modified NRP1 specific antisense oligonucleotides (ASOs) that effectively knockdown target gene …